Search
The leaders of London based LabGenius Therapeutics discuss a recent ESMO IO poster for their Nectin-4 x CD3 T-cell engager, and a new expanded collaboration with Sanofi on antibody optimization
CEO James Field and CSO Angus Sinclair discuss the Nectin-4 bi-specific, which is meant to have increased selectivity and potency and will compete with ADCs that are already on the market. Plus, how they are using their ML/AI expertise to help Sanofi with new programs.
23 hours ago
James Field describes how LabGenius is using machine intelligence to design the next generation of multispecific antibodies
LabGenius is combining in silico design and automation to optimize antibody design, oftentimes with a non-obvious result.
Apr 30, 2024
.png){kind=logo}
